Abstract 684P
Background
A diagnosis of, or progression to, advanced prostate cancer (PCa) and its treatment with chemotherapy (chemo) will impact a man’s quality of life (QoL). Since life expectancy of these men is expected to be limited after receiving chemo, QoL will likely be most important during the final stages of their lives. Europa Uomo, the patient organization for men with PCa in Europe, initiated a unique patient-driven QoL study, with the aim of providing a patient-driven prognosis after treatment. Here, we describe how chemo affects men’s QoL.
Methods
Treated PCa patients in Europe were invited to complete a one-time, online survey through the network of Europa Uomo. The survey included demographical questions and the items of the validated EQ-5D-5L, the EORTC-QLQ-C30 and the Expanded Prostate Cancer Index Composite short form 26 (EPIC-26). The survey was available in 19 languages.
Results
Between Aug 21-Nov 19, 2019 2, 943 men from 24 European countries completed the EUPROMS survey. 246 men (8.4%) indicated that they ‘ever had chemo’, either as a single treatment or in combination with other treatments. Median age of men who completed the survey and ‘ever had chemo’ was 70 years (IQR 64-75). With respect to the EQ-5D-5L, 49.6% experienced problems with mobility, 72.8% were able to take care of themselves, 46.7% has slight/moderate problems with their usual activities, 61.8% reported slight/moderate pain/discomfort and 60.1% reported some form of anxiety/depression. The EORTC-QLQ-C30 revealed that most symptoms were measured on scales of fatigue, pain and insomnia. With respect to prostate-specific function EPIC 26; the median score for urinary incontinence was 83.4 (IQR 53.8-95.0), 58.3 (IQR 45.8-69.1) for the hormonal domain, and 12.5 (IQR 4.2-18.0) for sexual function. EPIC 26 functions were calculated from 0 to 100, with 100 representing better function.
Conclusions
Our PCa patient-reported outcome data on QoL after chemo show that this type of treatment affects all areas of health-related QoL, with especially high levels of reported fatigue, pain, and insomnia. These outcomes underline the need for pre-treatment counselling, not only on expected oncological outcome but also on the potential impact on QoL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Europa Uomo.
Funding
Bayer, Ipsen and Janssen Pharmaceutica.
Disclosure
All authors have declared no conflicts of interest.